Bauer L A, Blouin R A, Griffen W O, Record K E, Bell R M
Am J Hosp Pharm. 1980 Apr;37(4):519-22.
The pharmacokinetics of single-dose amikacin sulfate was studied in seven morbidly obese patients to determine the fraction of fat weight (FW) that, when added to ideal body weight (IBW), will normalize the volume of distribution. Seven patients (mean total body weight of 166.5 kg) were each given a 1,250-g intravenous injection of amikacin. Amikacin serum levels over eight hours were measured by radioimmunoassay. A correction factor (CF) of 0.38 was found to normalize the patients' volume of distribution (Varea) to 0.26 liters/kg, when added to the patients' IBW. There was no significant difference between peak amikacin levels predicted using the actual Varea and using the Varea plus the CF. Predictions using the actual Varea and those using Varea estimated by ideal body weight were significantly different. In morbidly obese patients, peak amikacin serum levels can be predicted best when a volume of distribution based on IBW plus a correction factor of 38% of FW is used.
对7名病态肥胖患者进行了单剂量硫酸阿米卡星的药代动力学研究，以确定将脂肪重量（FW）的哪一部分加到理想体重（IBW）上时，分布容积会恢复正常。7名患者（平均总体重166.5千克）每人静脉注射1250毫克阿米卡星。通过放射免疫测定法测量8小时内的阿米卡星血清水平。发现校正因子（CF）为0.38，当加到患者的IBW上时，可使患者的分布容积（Varea）恢复正常至0.26升/千克。使用实际Varea预测的阿米卡星峰值水平与使用Varea加上CF预测的峰值水平之间无显著差异。使用实际Varea的预测与使用理想体重估计的Varea的预测有显著差异。在病态肥胖患者中，当使用基于IBW加上FW的38%的校正因子的分布容积时，阿米卡星血清峰值水平的预测效果最佳。
